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Understanding the biological pathways critical for common neuroﬁbromatosis
type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour
biomarkers, prognostic factors and therapeutics. We used gene expression
proﬁling to deﬁne transcriptional changes between primary normal Schwann
cells (n¼10), NF1-derived primary benign neuroﬁbroma Schwann cells (NFSCs)
(n¼22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n¼13),
benignneuroﬁbromas(NF)(n¼26)andMPNST(n¼6).DermalandplexiformNFs
were indistinguishable. A prominent theme in the analysis was aberrant differ-
entiation. NFs repressed gene programs normally active in Schwann cell pre-
cursors and immature Schwann cells. MPNST signatures strongly differed; genes
up-regulated in sarcomas were signiﬁcantly enriched for genes activated in
neural crest cells. We validated the differential expression of 82 genes including
the neural crest transcription factor SOX9 and SOX9 predicted targets. SOX9
immunoreactivity was robust in NF and MPSNT tissue sections and targeting
SOX9 – strongly expressed in NF1-related tumours – caused MPNST cell death.
SOX9 is a biomarker of NF and MPNST, and possibly a therapeutic target in NF1.
INTRODUCTION
A genetic defect underlies NF1, which is inherited as an
autosomal dominant trait affecting 1:3,000 humans (Rasmussen
& Friedman, 2000). Analysis of progressive changes down-
stream of NF1 mutation has been complicated by the spectrum
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types involved. The hallmark of NF1 is the development of
peripheral nerve sheath tumours. At least 95% of NF1 patients
have multiple dermal NFs, benign tumours that typically appear
in adolescence (Rasmussen & Friedman, 2000). Approximately,
30% develop plexiform NFs that are larger, may cause
signiﬁcant morbidity, and can occur congenitally. Questions
as fundamental as whether there are molecular differences
between dermal and plexiform NF are to date unanswered.
Differences between the types of NF are implied as a plexiform
NF may transform to an MPNST, a life threatening sarcoma
(Evans et al, 2002).
The sequence of biological events driving MPNST
formation is unknown. Beyond mutations in both copies of
the NF1 tumour suppressor gene (Wimmer et al, 2006), few
molecular alterations have been associated with NFs and/or
MPNSTs. These alterations include the epidermal growth factor
receptor (EGFR), detected in MPNST cell lines and in a
subpopulation of NFSCs, as well as ampliﬁcation of KIT,
PDGFRA and PDGFRA mutations, detected in MPNSTs. Loss of
tumour suppressor genes, including TP53, RB or INK4A, have
been documented in NF1-associated MPNSTs but not NFs
(reviewed in Carroll & Ratner, 2008).
Dermal and plexiform NFs are composed of cell types present
in normal nerves but in a disorganized form. Axon–Schwann
cellcontact,whichregulateskeyaspectsofnormalSchwanncell
function, is disrupted in NFs. NFSCs are found distant from
axonsinacollagen-rich extracellular matrix,admixedwithmast
cells and ﬁbroblasts (Cichowski & Jacks, 2001). Methods were
developed to purify normal human Schwann cells (NHSCs) and
NFSCs (Serra et al, 2000). We hypothesized that comparing the
gene expression in cultured Schwann cells could identify
changes relevant to tumourigenesis because within NFs, only
Schwann cellsexhibit biallelicNF1 mutations (Serraetal, 2000).
NFSCs also show elevated levels of Ras-guanosine triphosphate
(GTP) (Sherman et al, 2000), consistent with neuroﬁbromin
functioning as a GTPase activating protein (GAP) that
inactivates Ras (Le & Parada, 2007), and invade basement
membranes and stimulate angiogenesis whereas normal
Schwann cells do not (Sheela et al, 1990). Thus, while the
datastrongly support theview thatSchwann cells arethe crucial
pathogenic cell type in NFs, the molecular changes in NFSCs
that drive tumourigenesis are largely unknown.
The critical period(s) in Schwann cell development at which
an NF1 mutation results in NF and/or MPNST is also not clear
(Carroll & Ratner, 2008; Le et al, 2009; Williams et al, 2008).
Schwanncellsoriginatefromneuralcreststemcellsanddevelop
into Schwann cell precursors, then immature Schwann cells and
ﬁnally mature Schwann cells (Jessen & Mirsky, 2005). The SOX
family of transcription factors is important for neural crest stem
cell survival (Cheung et al, 2005); SOX10 is required for glial
speciﬁcation in the peripheral nervous system (Britsch et al,
2001). Analysing the expression of these genes might provide
insight into the timing of tumourigenesis.
Gene expression in NF1-associated tumours has been
analysed by quantitative real time-polymerase chain reaction
(qPCR) (Levy et al, 2004), subtractive hybridization
(Holtkamp et al, 2004) and cDNA (Miller et al, 2003) and
oligonucleotide (Levy et al, 2007; Miller et al, 2006) microarray
analyses. Direct comparison of these studies is unfortunately
limited due to the multiplicity of platforms and technical
variability in sample processing among the different labora-
tories. To identify a molecular progression model for NF1
peripheral nerve tumourigenesis, we formed the NF1 micro-
array consortium and analysed primary tumour-derived
Schwann cells, MPNST cell lines and NF1 solid tumours.
RESULTS
Creation of a comprehensive gene expression data set
consisting of primary tumour-derived Schwann cells, MPNST
cell lines and NF1 peripheral nerve tumours
NF tissue samples contain NF1þ/  and NF1 /  Schwann cells,
ﬁbroblasts, perineurial cells, endothelial cells and mast cells. To
avoid this inherent variability and to describe gene expression
changes that correspond to a single cell type, we used puriﬁed
Schwann cells as the basis for our analysis. To ensure data
quality, we minimized non-biological variability in sample
batch processing by running samples from each experimental
group in each processing batch. To minimize the technical
variability, a single individual (AH) isolated RNA and we
conducted microarray hybridization at a single site. We also
hybridized a universal reference RNA in each processing batch
along with 11NF related RNAs as a technical control for batch-
to-batch variation. Analysis after each processing batch
assessed the power for statistical comparisons (Page et al,
2006). We also used power analysis as a futility analysis in the
comparison of dermal and plexiform NFs to determine that a
differencebetweenthegroupswouldnotbedetectablewithouta
far larger sample size (at minimum, 5  more samples).
Schwann cell culture transcription profiles distinguish benign
from malignant NF1 tumours but fail to discriminate NF
subtypes
To discover gene expression programs that underlie the
differences between cultured NHSCs, dermal and plexiform
NFSCs (dNFSCs and pNFSCs, respectively) and MPNST cell
lines, after referencing (see the Materials and Methods section),
analysis of variance (ANOVA) identiﬁed 2,827 transcripts
(FDR 0.001) as differentially expressed that we, then,
subjected to two-way hierarchical tree clustering (Fig 1 and
Table S1 of Supporting Information). Most MPNST cell lines
display a unique transcriptional signature and cluster to the far
right of the heat map, separately from benign NF-derived
Schwann cells. Although we anticipated gene expression
signatures that were unique to dNFSCs or pNFSCs, transcripts
that passed the ANOVA failed to partition the two NF subtypes.
Direct comparison of dNFSCs and pNFSCs also failed to identify
a statistically signiﬁcant signature. Instead, we observed two
classes of NFSCs, with genes in Class 1 NFSCs (Fig 1; green bar
beneath heat map) less up- or down-regulated than genes in
Class 2 NFSCs (Fig 1; blue bar beneath heat map). Class type did
not correlate with any known patient parameters or sample
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identiﬁed and genes were assigned to each using k-means
clustering (clusters C1–C5; Fig 1 and Table S2 of Supporting
Information; see Table S3 of Supporting Information for
biological associations and Table S2 of Supporting Information
for detailed cluster and biological association gene lists).
Transcripts differentially expressed in NF1 tumour cell
cultures share gene expression signatures with NF1 solid
tumours
Each cluster from Fig 1 was re-clustered across NHSCs, primary
NFs and primary MPNSTs. We identiﬁed sub-cluster(s) that
weresimilarlyexpressedacrosscellculturesandtheirrespective
solid tumour type. After assigning genes using k-means
clustering (Fig 2; Table S5 of Supporting Information), we
evaluated clusters C6–C11 to explore the potential biological
signiﬁcance of transcripts deregulated in both NF1 tumour cell
cultures and solid tumours (Tables S5 and S6 of Supporting
Information). Two-way hierarchical cluster analysis of the
transcripts (n¼1,708; 1,108 unique genes) that were similarly
expressed in cell cultures and solid tumours again failed to
segregate dermal and plexiform NF tumours (Fig 2). The
complete list of genes is shown in Table S4 of Supporting
Information.
Analysis of functional enrichment for genes in clusters
C6–C11 showed signiﬁcant associations with nervous system
development. We used GATACA
1 to identify transcripts from
each over-represented ontology or pathway in each cluster
associated with nerve development and/or NF or MPNST.
Genes in cluster C6 were associated with nervous system
development and were down-regulated in most of the sample
types (variablydown-regulatedinclass1NFSCs andsomeNFs).
Cluster C6 included EMP2, EPB41L3, GFAP, HLA-DQB1, KLK6,
L1CAM, LGI1, MBP and NGFR. Genes in cluster C7 were
associated with neurogenesis. Cluster C7 consisted of genes
down-regulated in MPNST cell lines, MPNSTs and most of the
NFs (variable in Class 2 NFSCs and some NFs) and included
CDKN2A, CTSD, GJB1, GNAI2, HPCAL1, KNS2, MF12, NES and
NFKB1. Genes in cluster C8 were associated with nervous
system development. Cluster C8 exhibited decreased expression
in most of the MPNST cell lines (variable in MPNSTs and class 2
NFSCs) and contained transcripts that included BCL2, BCL2L2,
EDNRB, ERBB3, MPZ, PDGFA, PDGFB and S100b. Transcripts in
cluster C9 were associated with morphogenesis and nervous
system development. Genes in cluster C9 were up-regulated in
Research Article
Gene expression in neurofibroma and MPNST
Figure 1. Heat map of transcripts differentially expressed between
cultured NHSCs and cultured dNFSCs, pNFSCs and MPNST cell lines.
Two-way hierarchical clustering grouped samples as either NHSCs, mixed
benigndNFSCand pNFSCormalignanttumour (MPNST)cell lines.Twoclasses
of NFSCs are identifiable, with Class 1 NFSC (green bar beneath the heat map)
expression levels attenuated relative to Class 2 NFSC (blue bar beneath the
heat map) levels. Genes in clusters C1 and C4, which show decreased or
increasedexpressionin benigntumours, respectively, andoppositeexpression
in MPNST cell lines (indicated with asterisks), are abundant in genes
associated with cell cycle (AURKA, CDC25B, CDKN2A, CNAP1, INHBA, MCM7,
PDGFB) and cell differentiation (ADAM12, ANGPTL4, BMP1, CHL1, IL11, INHBA,
PPL, SERPINE2). The bar to the right of the heat map shows five clusters
(C1–C5), corresponding to k-means functional clusters listed in Tables S2 and
S3 of Supporting Information.
Figure 2. Heat map of transcripts similarly expressed in NF1 cell cultures
and tumours. Differentially expressed transcripts in NF1 peripheral nerve cell
culture samples were filtered to identify genes with similar patterns of
expression in solid tumours. A total of 1,708 transcripts (60%) were identified
and clustered across NHSCs, dNFSCs, pNFSCs, MPNST cell lines (annotated as
in Fig 1), and dNFs, pNFs and MPNSTs. The bar to the right of the heat map
shows five clusters (C6–C11), corresponding to k-means functional clusters
listed in Table S5 of Supporting Information.
1gataca.cchmc.org
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PAX6, SMAD3 and WT1. Transcripts in clusters C10 and C11
were associated with skeletal development, and C11 with
morphogenesis. Genes in cluster C10, variably up-regulated in
Class 1 NFSCs and up-regulated in all others, included APOD,
CASP1, CD36, EGFR, KIT, LEPR, MME and SOCS3. Cluster C11
was composed of transcripts that were up-regulated in class 2
NFSCs,MPNSTcelllinesandMPNSTs(variableinclass1NFSCs
and NFs) and contained ADM, CAPN1, FBN2, IGFBP3, PDGFRA,
PIAS3,PLAU,PTGES,PTGS2andTFPI.ClusterC11alsoincluded
the neural crest markers TWIST1 and SOX9, and exhibited
increased expression in all samples. Additional functional
annotation categories for each cluster are shown in Tables S5
and S6 of Supporting Information.
NF1 tumour cell culture and solid tumour expression
patterns show broad dysregulation of genes activated in
developing Schwann cells
The high representation of genes associated with Schwann cell
development in the NF1 tumour signature led us to compare the
1,708 gene signature (1,108 unique genes) to gene orthologues
activated in migrating neural crest cells and two stages of
Schwann cell development, Schwann cell precursor and
immature Schwann cell, based on a published data set
(Buchstalleretal,2004)(Table1).Strikingly,alldown-regulated
clusters (C6–C8) showed signiﬁcant enrichment for gene
orthologues activated in immature Schwann cells. Genes up-
regulated in MPNST (cluster C9) demonstrated signiﬁcant
over-representation of gene orthologues activated in migrating
neural crest cells. The repression of transcripts normally
expressed late in Schwann cell development and activation of
genes normally expressed early is consistent with signiﬁcant
over-representation of developmental themes identiﬁed in our
functional analysis (see Tables S4 and S5 of Supporting
Information).
In cluster C11, we identiﬁed the neural crest markers TWIST1
andSOX9.TWIST1 inhibitsMPNST cellchemotaxis (Miller etal,
2006). ManySOXfamilymembersaredifferentially expressedin
NF1 samples relative to normal Schwann cells, including down-
regulation of SOX5 (clusters C6 and C7), SOX2, SOX2OT, SOX8,
SOX10 and SOX 13 (cluster C8) and up-regulation of SOX11
(cluster C9) and SOX9 (cluster C11).
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Table 1. NF-related peripheral nerve cell culture and tumour transcription patterns are enriched for genes regulated during Schwann cell development
Cluster Expression
pattern
Unique
genes
Unique in
9,137
Migrating
neural crest
2,033 of 9,137
unique genes
Schwann cell
precursor
778 of 9,137
unique genes
Immature
Schwann cell
1,421 of 9,137
unique genes
Expect Observed Significance Expect Observed Significance Expect Observed Significance
C6 Down in all,
variable in class
1 NFSCs and
some NFs
232 88 20 8 1.80E-03 7 12 8.53E-02 14 26 9.08E-04
C7 Down in all except
class 1 NFSCs,
variable in class
2 NFSCs and
some NFs
321 133 30 22 1.16E-01 11 19 2.65E-02 21 34 2.42E-03
C8 Down in most
MPNST cell lines,
variable in MPNSTs
and class 2 NFSCs
245 91 20 6 1.08E-04 8 6 7.04E-01 14 54 2.20E-16
C9 Up in MPNST cell
lines and MPNST
175 69 15 31 2.84E-05 6 2 1.25E-01 11 7 2.46E-01
C10 Up in all, variable in
class 1 NFSCs
90 46 10 5 7.41E-02 4 7 1.09E-01 7 10 2.26E-01
C11 Up class 2 NFSCs,
MPNST cell lines
and MPNSTs, variable
in class 1 NFSCs
and NFs
123 71 16 15 8.87E-01 6 10 1.29E-01 11 12 7.42E-01
Each of the k-means clusters identiﬁed in Fig 2 (C6–C11) was evaluated for over-representation of gene orthologues characteristic of three stages of Schwann cell
development. We ﬁrst generated orthologue gene lists for transcripts up-regulated in migrating neural crest, Schwann cell precursors and immature Schwann
cells (Buchstaller et al, 2004). After correcting for redundant probe sets, lack of corresponding gene orthologues and platform-speciﬁc gene representation
differences, Fisher’s exact test was used to calculate the expected overlaps between k-means clusters and each of the orthologue gene lists. All down-regulated
clusters (C6–C8) showed signiﬁcant enrichment for gene orthologues activated late in Schwann cell development (i.e., immature Schwann cells). Up-regulated
gene clusters characteristic of MPNST were C9, enriched for gene orthologues activated early in Schwann cell development (i.e., migrating neural crest) and C10,
enriched for gene orthologues up-regulated in Schwann cell precursors. Gene orthologues activated in Schwann cell precursors but down-regulated in all samples
except Class 1 NFSCs, variable in Class 2 NFSCs and variable in some NFs were also signiﬁcantly over-represented in cluster C7.
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expression of 82 genes in at least one sample from each sample
type by qPCR. Differential expression of 41/82 genes was
conﬁrmed in all samples and 77/82 genes in at least 50% of the
samples (Table S7 of Supporting Information). This conﬁrma-
tion rate is comparable to that reported in other studies. The
entire data set is publicly available via Gene Expression
Omnibus
2 (Accession number GSE14038).
SOX9 is over-expressed in NF1-derived peripheral nerve
tumours
SOX9 is a neural crest transcription factor required for stem cell
survival (Cheung et al, 2005). Our microarray data show over-
expression of SOX9 in all NF1 tumour samples, ranging from
1.5- to 137-fold on the microarray. Average SOX9 expression
values were at least two-fold higher in MPNST samples relative
toNFsamples(Fig3A).ConﬁrmationofSOX9wasconductedby
qPCR,eitherusingcDNAsynthesizedfromRNAsamplesusedto
generate probes for microarray hybridization (Technical) or
independent RNA samples (Biological) (Fig 3B). SOX9 over-
expression was then validated at the RNA (Fig 3B) and protein
(Fig 3C) levels in independent cultures of human NFSCs and
MPNST cell lines.
Immunohistochemical analysis of SOX9 protein expression
was conducted in a panel of 42 NF1 tumour sections, 10 of
which were independent of the gene expression microarray
experiment (Fig 3E). Strikingly, SOX9 expression was detected
in all the tumours, and the staining intensity was similar in all
NF and MPNST samples (strong). In the majority of dermal NFs,
<30% of the cells were SOX9-positive. The majority of
plexiform NFs contained  50% SOX9-positive cells, while
>70% of the cells were SOX9 positive in the MPNSTs.
Research Article
Gene expression in neurofibroma and MPNST
Figure 3. SOX9 is over-expressed in NF1 tumours
relative to Schwann cells.
A. Boxplot of SOX9 gene expression microarray
data in each of the seven sample types
normalized to Schwann cell gene expression
(NHSC). Horizontal lines in each bar represent
the median SOX9 expression within each
sample type and the error bars indicate the
range of non-outlier measurements.
B. SOX9 mRNA expression measured by qPCR of
individual samples within each sample type
and normalized to expression in Schwann
cells (NHSC). Fold-change values were
transformed to log 10 scale in order to display
MPNST samples (ranging from 1,448- to
1,72,950-fold) and NF samples (ranging from
20- to 6,654-fold) on the same graph.
Validation of RNA samples that were analysed
by microarray (Technical) include: 1–3,
NHSCs; 4, dNFSCþ/ ; 5, dNFSC / ; 6, dNF; 7,
pNFSC; 13, pNF; 14, 22, MPNSTs. Validation of
independent RNA samples (Biological)
include: 8–12, pNFSCs; 15–21, MPNST cell
lines; 15, STS26T; 16, ST8814; 17, S462; 18,
T265; 19, 90-8; 20, 88-3; 21, YST1.
C. SOX9 protein expression in Schwann cells
(NHSC), MPNST cell lines (26T, 8814, S462,
T265) and pNFSC by Western blot (top panel)
analysis. b-actin was used as a loading con-
trol.
D, E. Immunohistochemical detection of SOX9 in a
representative NF and MPNST tissue section
with extensive SOX9 expression. Cells stained
brown are positive for SOX9. (e) The
percentage distribution of SOX9-positive cells
in a panel of dNF, pNF and MPNST sections.
The majority of samples screened were
represented in the microarray analysis with
the addition of ten independent samples,
including three dNFs, five pNFs and two
MPNSTs.
F. Immunofluorescent detection of SOX9
(TRITC¼red) and nuclei (DAPI¼blue) in
cultured NHSCs, NFSC and ST8814
NF1-derived MPNSTcells. Similar results were
obtained in STS26T sporadic MPNST
cells (data not shown). Fields shown are
representative of each population. Merging
fluorescent images detecting DAPI and TRITC
(Merge) highlights nuclear localization of
SOX9, mainly in MPNST.
2http://www.ncbi.nlm.nih.gov/geo/
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MPNST cells, variable in NFSCs and excluded from the nucleus
in normal Schwann cells (Fig 3F).
Differential diagnoses for NFs include schwannomas, benign
Schwann cell tumours without NF1 mutations. In a panel of
eleven schwannomas stained for SOX9, ﬁve were negative or in
background only, three had weak positive staining and three
had moderate staining in <25% of the cells (data not shown). A
differential diagnosis for MPNST is synovial sarcoma. Out of
seven synovial sarcomas stained, four were negative, two had
weak, focal positivity and only one displayed strong staining in
most of the cells. These data support the conclusion that SOX9 is
a biomarker for NF and MPSNT.
Reducing SOX9 expression inhibits MPNST cell survival
To test for a role for SOX9 in tumourigenic cellular behaviour,
we used short hairpin RNAs (shRNAs) to reduce SOX9
expression in NF (Fig 4A) and MPNST cells (Fig 4C–E) relative
to a non-targeting control. A decrease in SOX9 expression
signiﬁcantly reduced MPNST cell survival (Fig 4F), correlating
with a decrease in cell accumulation (Fig 4G) and an increase in
cell death (Fig 4H); shRNAs directed towards ﬁve other genes
(data not shown) did not affect MPNST cell survival. Similar
results were obtained in two independent MPNST cell lines.
Reducing SOX9 expression with shRNA to a level obtained in
MPNST cells (Fig 4A) had a milder effect on NFSC survival
(Fig 4B) and little or no effect onnormal Schwann cells (data not
shown). The reduced effect of SOX9 expression in NFs is not
solely a function ofthe passage number, sinceNFSCs expressing
SOX9 shRNAs for several passages showed only a 10–20%
reduction in growth rate. These data suggest that MPNST cells,
not NF cells, are critically dependent upon SOX9 expression for
survival.
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Figure 4. Reducing SOX9 expression in NF1 tumour
cells inhibits survival.
A. Confirmation of reduction in SOX9 RNA
expression in NFSCs.
B. NFSCs infected with lentivirus expressing
SOX9 shRNA or non-specific shGFP control
were plated 7 days post-selection in
puromycin to measure cell survival in 4 days
using an MTS assay. A trend towards a
decrease in cell survival was observed in
shSOX9-expressing cells compared to
shGFP-expressing cells but was not
statistically significant. The corresponding
phase contrast images to the right show
NFSCs infected with shGFP (NFSC shGFP) or
SOX9 shRNA (NFSC shSOX9).
C–E. Confirmation of reduction in SOX9 RNA
expression in MPNST cells by qPCR (c) and
SOX9 protein expression by western blot (d, e).
Expression levels were measured 1 day (d) or
7 days (c, e) post-selection in puromycin and
normalized to the non-specific shGFP control.
Expression of b-actin was used as a control.
F. Reduction in MPNST cell number (18-fold) in
the presence of SOX9 shRNA relative to shGFP
control. Cells were plated in triplicate and
represent three independent infections
(
 p¼0.05). The top right panel represents the
confluent dish of MPNST cells infected with
shGFP lentiviral particles three days post-
selection with puromycin; bottom right panel
represents dying MPNST cells infected
with shSOX9 lentiviral particles three days
post-selection with puromycin. Similar results
were observed with three different SOX9
shRNAs.
G. MPNST cells were infected with shGFP or
shSOX9 lentiviral particles for MTS analysis of
cell accumulation during a time course of
1–4 days post-selection in puromycin. Cells
were plated in triplicate in the presence or
absence of puromycin to account for infection
efficiency. All shRNAs infect with similar
efficiency at greater than 90%. Values are
corrected for infection efficiency and
represent three independent infections.
H. MPNST cells treated as described in (c–e) and
assayed for apoptosis by TUNEL staining three
days post-selection in puromycin. Uninfected
and shGFP-infected cells have similar
numbers of TUNEL-positive cells with a
significant increase in TUNEL-positive cells in
the presence of shSOX9 (
  p¼0.002).
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cultures and solid tumours are enriched for SOX9 target
genes
SOX9 transcriptional targets described in the literature for other
cell types were not signiﬁcantly altered in our data set (Panda
et al, 2001). However, an analysis of SOX9 binding sites (Mertin
et al, 1999) in the promoters of 1,108 unique genes in the NF1
tumour signature revealed >2  potential SOX9 targets relative
to the entire genome than expected by chance (39 transcripts as
compared to the predicted 18, Fisher’s exact test, p¼8.45
 06;
Table S8 of Supporting Information). To provide preliminary
evidence supporting predicted SOX9 transcriptional targets, we
analysed the expression of six putative target genes in MPNST
cells expressing three independent shSOX9 RNAs as compared
to MPNST cells expressing control shRNA. Expression of four
out of six (EYA4, DPYSL3, GFRA1 and FOSL2) genes tested were
signiﬁcantly changed in response to reduction in SOX9
expression (Table S9a of Supporting Information). In contrast,
neural crest and Schwann cell differentiation markers (TWIST1,
SOX10, PMP22 and NGFR) were not signiﬁcantly changed by
SOX9 reduction (data not shown). To test whether increase in
SOX9 can affect target gene expression, we infected NHSCs and
NFSCs with an adenovirus encoding mouse Sox9 and analysed
the expression of the same six putative target genes. The
expression of 5/6 genes were signiﬁcantly altered in NHSCs and
4/6 in NFSCs implying that Sox9 is sufﬁcient to, directly or
indirectly, regulate these genes (Table S9b of Supporting
Information). Similar to what we observed in MPNST cells
expressing shSOX9 RNA, FOSL2, DPYSL3, EYA4 and CHD13
expression were each altered in normal and NFSCs by increased
Sox9 expression.
DISCUSSION
We provide a wealth of high-quality, comprehensive data for
the NF1 research community. Embedded within the gene
signatures of NFs and MPNSTs lie potential biomarkers and
molecular targets for future therapeutic development in NF1,
including SOX9. Comparing gene expression proﬁles of NF1
tumour samples to cultured primary Schwann cells resulted in a
1,108uniquegenesignaturedistinguishingNF1tumoursamples
from normal Schwann cells. Identifying gene expression
differences in cultured MPNST cell lines, NFSCs and normal
Schwann cells avoided the complex heterogeneity inherent to
solid tumours; using the cell culture gene signature to identify
common gene expression patterns, in the solid tumours, which
allowed us to identify the Schwann cell component.
The data did not allow us to directly evaluate differences
between tumour types that are independent of Schwann cells
(e.g. microvasculature, additional cell types). We did observe
differences in gene expression between cell cultures and their
respective solid tumour type, which could represent the
inﬂuence of the tumour microenvironment. We anticipate that
future studies will use this data set to dissect the molecular
contribution of other NF-derived cells, including ﬁbroblasts,
mast cells and endothelial cells. This will be important as
NF1þ/  mast cells and ﬁbroblasts show NF-relevant properties
(reviewed in Cichowski & Jacks, 2001; Le & Parada, 2007) and,
in some mouse models of NF1, an Nf1þ/  background
enhanced tumour development when Nf1 was ablated in
Schwann cells (Zhu et al, 2002).
Surprisingly, cluster analysis of global gene expression
microarray data did not distinguish dermal and plexiform
NFs, although MPNSTs normally arise only from plexiform NFs.
Dermal and plexiform NF cells may be inherently the same but
exposed to different environments, as the dermal NF is typically
cutaneous and the plexiform NF sub-cutaneous. Another
possibility is that different molecular alterations initiate the
formation of dermal or plexiform NFs but converge on a
common molecular pathway. It is also possible that small
populations of tumour stem cells with the potential for
malignant transformation exist within a plexiform NF tumour
cell sub-population but that gene expression within this small
subset would not be identiﬁed by our analysis.
Two distinct classes of NF samples were identiﬁed by
transcriptional proﬁling, designated Class 1 and Class 2. Each
class includes Schwann cells from dermal and plexiform NFs.
There was no clear patient phenotype associated with these
classes, although we recognize that more precise patient
information and larger series of cases may reveal a possible
correlation. Class 1 transcriptional patterns are more similar to
NHSCs than Class 2 transcriptional patterns, and both classes
were represented in NFSCs in vitro. A small number of primary
tumours also showed a Class 1 pattern, indicating a possible
relevance to a speciﬁc stage in tumour growth or differentiation
that is maintained in vitro; the majority of primary tumours
show a Class 2 pattern.
Of interest are genes that are ampliﬁed in array CGH but
which we found to be decreased in expression, such as the
SOX10transcriptionfactor(Mantripragadaetal,2008).Silencing
of these genes may be relevant to tumour progression. SOX10 is
expressed throughout the Schwann cell lineage in neural crest
cells and mature Schwann cells (Kuhlbrodt et al, 1998). SOX10
normally promotes cell survival in the neural crest, speciﬁcation
in Schwann cell progenitors and myelin production in mature
Schwann cells (Schreiner et al, 2007). Sox10-deﬁcient mice lack
glial cells in the peripheral nervous system (Britsch et al, 2001).
SOX10 activates transcription of myelin genes, including MPZ
(Peirano et al, 2000) and MBP (Wei et al, 2004), also down-
regulated in NF1 tumours. While SOX8 can compensate for lack
of SOX10 function (Kellerer et al, 2006), SOX8 expression is
down-regulated in NF1 tumours. Reduced expression of SOX10
in NF1 tumours suggests that the decreased expression may be
necessary for tumour formation. Low SOX10 expression in
tumour Schwann cells is also consistent with failure of complete
differentiation, based on our ﬁnding that gene expression
proﬁles of NF1 tumours down-regulate expression of Schwann
cell progenitor and immature Schwann cell genes.
Miller et al (Miller et al, 2006), using the strategy applied here
(e.g. Schwann cell referencing) but using chips with lower
number of probe sets as compared to those studied here,
identiﬁed 162 probe sets differently expressed in MPNST cell
lines and MPNST tumours compared to normal Schwann cells.
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Sixteen are developmental genes, including TWIST1, SOX9,
CUGBP2, FEZ1, GAP43, GAS7, GPM6B, GPR56, LICAM, NGFR,
NRP2, PMP22, QKI, SEMA3B, SOX10 and ZFHX1B. In studies
that use different referencing strategies and technologies,
among 28 genes deﬁned as notably altered in expression 10
met our statistical criteria (FDR 0.001) and were changed
relative to a Schwann cell reference (Holtkamp et al, 2004;
Karube et al, 2006; Levy et al, 2004). Among the 10, the
developmentally regulated genes DHH, ERBB3, MPZ, S100b,
L1CAM and SOX10 are all down-regulated with respect to
normal Schwann cells.
Network analysis of the genes that distinguish NF-related
cells and tumours from Schwann cells did not reveal perturba-
tion of an obviously known molecular pathway. We expected to
identify gene expression changes downstream of Ras and EGFR,
because loss of NF1 causes hyperactivity of Ras signalling (Le &
Parada, 2007) and EGFR is abnormally expressed in NFs and
MPNSTs (DeClue et al, 2000; Perry et al, 2002). It remains
possible that transcriptional targets directly downstream of Ras
and EGFR in Schwann cells are present in our data set but
different from those that have been described in other cell types,
or that their expression changes were not sufﬁcient to pass our
cut-offcriteria,butnonethelessrepresentbiologicallysigniﬁcant
changes.
Comparison of the NF-related tumour gene expression proﬁle
to Schwann cell gene expression throughout development
(Buchstaller et al, 2004) indicated that NF cells fail to express
genes characteristic of immature Schwann cells and MPNST
cells express genes characteristic of more primitive neural crest
cells. Our study describes similarity of the differentiation state,
butnotthecelloforiginofNFsorMPNST.De-differentiationofa
mature Schwann cell to a Schwann cell precursor-like
phenotype cannot be excluded from our data. It is worth
mentioning that targeting Nf1 loss in a post-neural crest
compartment allowed for mouse NF formation (Wu et al,
2008). Losing the NF1 gene in a neural crest cell, inherently
proliferative and migratory, may produce a malignant cellular
phenotype (Fig 5). Joseph et al (2008) recently showed that
neural crest stem cells do not persist in Nf1; p53 mutant mice;
MPNST cells derived from these mice exhibit only some neural
crest-like features (Joseph et al, 2008). On the basis of their
ﬁndings, it may be more likely that MPNSTs form through de-
differentiation of the NFSC or Schwann cell precursor, which is
itself multipotent (Joseph et al, 2008), to a more primitive,
neural crest-like stage.
Consistent with MPNST and NF resembling different stages in
Schwann cell development, neural crest transcription factors
TWIST1 and SOX9 are expressed at higher levels in MPNST than
NFSCs and reducing SOX9expressionkills MPNST cells but has a
minimal effect onNF cell survival in vitro. SOX9 in the nucleus of
MPNST cells relative to NRSCs is consistent with higher SOX9
transcriptional activity in MPNST cells. SOX9 expression is also
up-regulated in neural crest-derived pheochromocytomas that
arise in Nf1 mutant mice (Powers et al, 2007). Sox9 may be
generally important in stem cells, as it regulates speciﬁcation of
epithelial stem cells (Nowak et al, 2008); in mice lacking Sox9,
neural crest cells apoptose (Cheung et al, 2005). High levels of
SOX9 expressioninMPNSTsappeartoresult in SOX9‘addiction’,
consistent with SOX9 being a lineage-survival oncogene in this
system (Garraway & Sellers, 2006). Increased levels of SOX9 may
not be sufﬁcient to drive proliferation characteristic of MPNSTs,
as in preliminary experiments in which we expressed SOX9 in
plexiform NFSCs, we observed no change in cell proliferation or
celldeath(AHand NR,unpublished).Analysisofsomaticgenetic
alterations of SOX9 in tumours and of effects of SOX9 on in vivo
tumourigenesis will be necessary to provide deﬁnitive evidence
that SOX9 is a lineage addicting/survival oncogene. In summary,
SOX9 expression provides a biomarker of NFs and MPNSTs.
Developing therapeutics aimed at diminishing SOX9 expression
or SOX9 transcriptional targets represents a strategy for killing
MPNST cells.
MATERIALS AND METHODS
NF acquisition
Diagnosis of NF1 used published criteria (Gutmann et al, 1997). We
snap froze tumour tissues at the time of surgery from patients
undergoing treatment at Massachusetts General Hospital. Tissues
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Figure 5. Model of NF1 peripheral nerve tumour
formation. SOX9 expression throughout the
Schwann cell lineage is inferred from work in
species other than human. Red represents high
SOX9 expression, yellow low SOX9 expression. (1)
dNF and pNF Schwann cells express intermediate
levels of SOX9 and show gene signature
characteristic of Schwann cell progenitors/
immature Schwann cells. (2A) A neural crest gene
signature is characteristic of MPNST cells, and
neuralcrestcellsareknowntoexpresshigherlevels
of SOX9 than more mature cells. (2A, 2B) Neural
crest cells may give rise directly to MPNST, or
MPNST may form indirectly via a NF-like cell
intermediate.
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Massachusetts General Hospital in accordance with IRB-approved
protocols. We obtained blocks of corresponding paraffin-embedded
tumours from MGH-pathology files. Histological review of all speci-
mens was performed by a neuropathologist (ASR) and tumours were
classified and graded using current WHO classification. For Schwann
cell isolation, we froze tumour in 50% Dulbecco’s modified Eagle’s
medium (DMEM), 40% foetal bovine serum (FBS), 10% dimethyl
sulphoxide (DMSO) or directly cultured cells. Live purified Schwann cell
cultures were shipped to Cincinnati Children’s Hospital, incubated in
fresh media until 70–80% confluent and cells flash-frozen prior to
RNA isolation.
Schwann cell isolation
We generated NHSCs from trauma victims (Casella et al, 1996), and
Schwann cells from dermal NFs as described previously (Serra et al,
2000). After mechanical trituration and digestion with enzymes, we
resuspended cells in Schwann cell media (SCM/DMEM supplemented
with 10% FBS, antibiotics, 0.5mM IBMX, 10nM b-heregulin, 0.5 mM
forskolin and 2.5mg/ml insulin) and seeded onto poly-L-lysine and
laminin coated plates. For NF1þ/ Schwann cells, we kept forskolin
constant. For NF1/ cells, we provided forskolin in pulses of 1 day every
3–4 days in SCM-no forskolin. We assessed the purity of Schwann cell
cultures by immunofluorescent staining with an S-100b antibody
(Serra et al, 2000). After 3–5 passages, >95% pure Schwann cell
cultures were obtained. When a somatic mutation of a tumour was
identified, we assessed purity according to genotype (Table S10 of
Supporting Information). In NF1/ Schwann cell cultures, complete loss
of heterozygosity (LOH) was observed. We generated plexiform NFSC
cultures, 70–95% S100b-positive, as described previously (Wallace et
al, 2000). We maintained cells in media lacking forskolin to enrich for
NF1/ cells, and harvested for RNA after 4–6 passages.
NF1 mutation analysis
We carried out mutational analysis of NF1 in Schwann cells from
dermal and plexiform NFs and in solid tumours as described
previously. Additional details are provided in Table S10 of Supporting
Information (Ars et al, 2000; Serra et al, 2001; Upadhyaya et al, 2006).
MPNST cell cultures
We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3,
90-8 and YST1 as described previously (Miller et al, 2006).We isolated
RNA from cells under standard growth conditions for each cell line.
RNA isolation and microarray hybridization
We isolated total RNA from frozen tissue and cells using the RNeasy
kit (Qiagen) and verified RNA integrity with an Agilent Bioanalyser
2100 (with typical 28S/18S ratios¼2 0.1). We generated biotiny-
lated cDNA probes from a single round of DNA displacement synthesis
amplification of 20ng total RNA (Ovation Biotin RNA Amplification
and Labelling System; NuGen) for hybridization to the whole-genome
Affymetrix GeneChip HU133 Plus 2.0 using the Affymetrix protocol.
We used an Affymetrix Gene Array scanner and GeneChip Operating
Software V1.4 to scan and quantify GeneChips using default settings.
We processed 86 samples in 9 batches, including: 9 universal tissue
reference samples, 10 NHSC samples, 11 dNFSC samples, 11 pNFSC
samples, 13 MPNST cell line samples, 13 dNF, 13 pNF and 6 MPNSTs.
We used Affymetrix Microarray Suite 5.0 to generate ‘CEL’ files for each
sample that were normalized using the Robust Multichip Analysis
(RMA) algorithm as implemented in Bioconductor/R (Irizarry et al,
2003).
Microarray data quality control and power analysis
We assessed array images for spatial defect using the GEODEX (Kim et
al, 2006) and a deleted residuals approach (Persson et al, 2005). Chips
with high spatial artefacts or large deviations from outliers (n¼2)
were discarded. One normalization control sample failed quality
control and we re-ran the entire batch of samples.
Data analysis strategy
We used a custom GeneChip library file (CDF) based on Refseq target
definitions (Hs133P REFSEQ Version 8) to provide accurate inter-
pretation of GeneChip data (Dai et al, 2005). To identify gene
expression changes relative to NHSCs, we applied a two-stage
referencing strategy: we set the normalized gene expression level
value for each transcript in each sample to its ratio relative to the
expression of that transcript’s measurement in the universal tissue
reference; then, we set the normalized gene expression level value for
each transcript in each sample to its ratio relative to the median
expression of that transcript’s measurements across NHSCs. An ANOVA
(p 0.001) was used to compare NHSCs, dNFSCs, pNFSCs and MPNST
cell lines. Statistical comparisons and data visualization were
performed using GeneSpring GX v7.3.1 (Agilent Technologies). We
corrected results from the primary analysis for multiple testing effects
by applying the Benjamini and Hochberg false discovery rate
correction (Benjamini et al, 2001) (FDR 0.001).
Transcripts were assigned to empirically defined expression patterns
using the k-means clustering algorithm, which generally finds a
clustering solution with a smaller within-cluster sum of distances
(meaning a more homogeneous cluster) than hierarchical clustering
techniques. We used Pearson correlation as a similarity measure and
iteratively clustered genes until convergence, then tested an
additional five random clusters to ensure that the optimal clustering
solution had been identified. To identify genes sharing common gene
expression patterns in cultured cells and solid tumours, we re-
clustered each cluster across NHSCs, NFs and MPNSTs. We identified
three principle patterns of gene expression and genes were assigned to
each using k-means clustering. We pooled sub-clusters displaying a
similar pattern of gene expression in NFs and MPNSTs as the original
cultured cell cluster with all other similarly expressed sub-clusters. A
total of 1,708 transcripts were obtained that were subsequently used
to generate a heat map including the entire sample set.
We identified statistically over-represented Gene Ontologies and
both KEGG and BioCarta pathways (p<0.05) using the Database for
Annotation, Visualization and Integrated Discovery (DAVID) 2007 at
the National Institute of Allergy and Infectious Diseases (NIAID)
(Huang da et al, 2007).We used the Gene Association to Anatomic and
Clinical Abnormalities (GATACA) web server to select genes based upon
association with nerve development, NF1 or MPNST.
Schwann cell development orthologues comparison
We used a data set in which Schwann cells were isolated from mouse
embryos using PLP promoter-driven GFP at various stages of
development (Buchstaller et al, 2004), and re-analysed the files
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trix). Probe sets were normalized per chip by a median intensity
distribution and then referenced to the median of each probeset
across the 19 microarrays in the data set. Probe sets were filtered for
those identified by Microarray Suite as ‘Present’ in  2 of the 19 arrays,
resulting in 8,617 probe sets. An ANOVA (p 0.2) was used to identify
the differential expression between E9, E12, E14, E16, E18 and P0.We
corrected the results for multiple testing effects by applying the
Benjamini and Hochberg false discovery rate correction (FDR 0.2).
The 4,750 identified probe sets were subjected to hierarchical tree
clustering using Pearson correlation similarity measure for genes
(average linkage) and distance correlation similarity measure for
samples (average linkage). Three major clusters were identified with
dominant expression at E9 (neural crest), E12–E14 (Schwann cell
precursor) and E18–P0 (immature Schwann cell) (Fig S1 of Supporting
Information). We eliminated redundant probe sets, lack of correspond-
ing gene orthologues and platform-specific gene representation
differences using orthologue gene mapping, and then tabulated the
overlap between each developmental signature and each cluster from
the NF1 tumour signature. Contingency tables were constructed and
we performed Fisher’s exact test with R to identify developmental
signatures that were statistically significant.
SOX9 target gene identification
We used Genome TraFac
3 for genome-wide detection of composi-
tionally similar cis-clusters in gene orthologues between mouse and
human to determine putative SOX9 target genes, identifying SOX9 cis-
elements within orthologue-conserved regions ( 70% sequence
similarity based on BlastZ alignment) upstream of each first exon in
2,000 flanking basepairs (Jegga et al, 2007). We identified 394 unique
genes containing potential SOX9 binding sites and transcripts
dysregulated in NF-related cultures and tumours. We used Fisher’s
exact test to calculate the statistical significance of over-represented
SOX9 target genes in the gene list.
qPCR
We conducted cDNA synthesis (Invitrogen Superscript II) and qPCR
(ABI 7500 Sequence Detection System) as described previously (Miller
et al, 2006). Primer sequences for target validation are shown in Table
S11 of Supporting Information. For technical validation of microarray
data, a result of   2-fold in the same direction was considered as
confirmation compared to expression of b-actin (Table S7 of
Supporting Information).
Western blot analysis
We created cell lysates and conducted Western blotting as described
previously (Miller et al, 2006), probed membranes with anti-SOX9
(Santa Cruz Biotechnology, Santa Cruz, CA; 1:700), then re-probed
with anti-b-actin (Cell Signaling Technology, Inc. #4967) as a loading
control. We detected signals using horseradish peroxidase-conjugated
secondary antibodies (BioRad; Hercules, CA) and the ECL Plus
developing system (Amersham Biosciences; Piscataway, NJ).
Immunohistochemistry
We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-
embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cam-
bridge, UK). Antigen retrieval was achieved with microwaving in sodium
citrate (pH6), followed by incubation with the primary antibody
overnight at 48C (1:75) and visualization with an avidin–biotin complex
(Vectastatin Elite ABC kit; Vector Laboratories, Burlingame, CA) and with
3,3’-diaminobenzidine tetrahydrochloride (Vector Laboratories, Burlin-
game, CA). We scored SOX9 immunostaining semi-quantitatively for the
number of positive cells, as the staining intensity was similar in all
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The paper explained
PROBLEM:
Neurofibromatosis type 1 (NF1) is one of the most common
inherited human diseases worldwide. Effective therapies are
lacking.Peripheralnervesheathtumours(neurofibromas)arethe
hallmark of NF1. They consist of benign dermal and plexiform
subtypes, but plexiform neurofibroma can transform to malig-
nant peripheral nerve sheath tumour (MPNST), a highly
aggressive, life-threatening sarcoma. Neurofibromas are com-
posed of multiple cell types, including Schwann cells, the
pathogenic cell type of NF1. The molecular changes that drive
tumourigenesis are largely unknown.
RESULTS:
The authors used DNA microarrays to profile the gene expression
in normal Schwann cells, Schwann cells cultured from primary
benign neurofibromas (dermal and plexiform subtypes), MPNST
cell lines and solid tumours. It was found that neurofibromas
repress gene programmes normally expressed in late-developing
immature Schwann cells, while MPNSTs activate gene
programmes normally expressed earlier in the development at
the neural crest stage. Strong expression of the transcription
factor SOX9 is seen in neurofibroma and MPNST tissue sections,
while schwannomas show weak or absent expression. Synovial
sarcomas, which may histologically mimic MPNST, are mainly
negative. Reduction of SOX9 expression in MPNST cell lines
causes cell death.
IMPACT:
SOX9 expression provides a biomarker of neurofibroma and
MPNST. Therapeutics aimed at decreasing SOX9 expression or
SOX9 transcriptional targets represent a strategy for killing
MPNST cells.
3http://genometrafac.cchmc.org/
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some), 25–75% (þ2, many) and >75% (þ3, maximum). Immuno-
fluorescent detection of SOX9 in cultured cells was conducted using a
1:200 dilution of primary anti-SOX9 antibody followed by a TRITC-
conjugated anti-rabbit secondary antibody and 4’-6-diamidino-2-
phenylindole (DAPI) visualization of nuclei.
Viral infection
For lentiviral shRNA infection, we infected MPNST cells at 70–90%
confluence with lentiviral particles containing shRNAs targeting SOX9
(Open Biosystems; TRC library) or GFP (Addgene). The CCHMC Viral
Vector Core
4 produced virus using a four plasmid packaging system.
We incubated lentiviral particles with the MPNST cells (MOI 10) in
the presence of polybrene (8mg/ml; Sigma) for 24h followed by
selection in puromycin at a concentration (2ug/ml) that killed
uninfected cells within 3 days. For SOX9 and GFP adenoviral infections
(Paul et al, 2003), we incubated viral particles with NHSCs or NFSCs
(MOI¼300–500) for 2h, replaced the growth medium and harvested
cells for RNA isolation 48 or 120h post-infection.
MTS assay
We plated MPNSTcells (4 10
3) in triplicate and incubated overnight
in a 96-well plate for infection with shGFP or shSOX9 lentiviral
particles as described previously. Cells were maintained in the
presence or absence of puromycin (2mg/ml) to account for infection
efficiency. We conducted MTS assays for viable cell number on days 3–
7 post-infection using the CellTiter 96
1 Aqueous One Solution Cell
Proliferation Assay (Promega).
Terminal deoxynucleotidyl transferase biotin-dUTP nick end
labelling (TUNEL) staining for cell death
We plated MPNST cells (2 10
4) in quadruplicate wells of LabTek
chamber slides (Nalge-Nunce International), and then infected them
with shSOX9 or shGFP lentiviral particles. After 3 days in the presence
or absence of puromycin, we fixed cells in 4% paraformaldehyde for
the detection of nuclear DNA fragmentation with the DeadEnd
Fluorometric TUNEL System (Promega; Madison,WI). One well without
terminal deoxynucleotidyl transferase was used as the negative
control. We counted cells in five random fields in triplicate wells. We
expressed Fluorescein isothiocyanate (FITC) positive apoptotic cells as
a percentage of total cells visualized by DAPI.
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